Mon, February 28, 2011
Sun, February 27, 2011
Fri, February 25, 2011
Thu, February 24, 2011
Wed, February 23, 2011
Tue, February 22, 2011
[ Tue, Feb 22nd 2011 ]: Market Wire
PROTOX APPOINTS NEW DIRECTORS
Mon, February 21, 2011
Sun, February 20, 2011
Fri, February 18, 2011
Thu, February 17, 2011
Wed, February 16, 2011
Tue, February 15, 2011
Mon, February 14, 2011
Fri, February 11, 2011
Thu, February 10, 2011

00 a.m. ET to Discuss Financial Results for the Fourth Quarter and Year Ended 2010


//health-fitness.news-articles.net/content/2011/ .. -for-the-fourth-quarter-and-year-ended-2010.html
Published in Health and Fitness on by Market Wire   Print publication without navigation



LEXINGTON, Mass.--([ BUSINESS WIRE ])--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the fourth quarter and year ended December 31, 2010 before the U.S. financial markets open on February 25, 2011. The announcement will be followed by a conference call and webcast with slides at 8:00 a.m. ET during which management will discuss the companya™s financial results, commercial progress and development programs.

To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 11:00 a.m. ET on February 25, 2011 through midnight February 28, 2011. To access a replay of the conference call, dial (800) 642-1687 from the United States or (706) 645-9291 for international access. The pass code for the live call and the replay is 44645136.

The call will be webcast with slides and accessible through the Investors section of the Companya™s website at [ www.amagpharma.com ]. The webcast replay will be available from approximately 11:00a.m. ET on February 25, 2011 through midnight March 25, 2011.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. AMAG manufactures and sells Feraheme® (ferumoxytol) Injection for intravenous use. For additional company or product information, please visit [ www.amagpharma.com ] or [ http://feraheme.com ].

Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.


Publication Contributing Sources

Publication Sponsors
[ Last Sunday ] - Oceanside Rental Gear